The causal relation between elevated levels of LDL-C and cardiovascular disease has been largely established by experimental and clinical studies. Thus, the reduction of LDL-C levels is a major target for the prevention of cardiovascular disease. In the last decades, statins have been used as the main therapeutic approach to lower plasma cholesterol levels; however, the presence of residual lipid-related cardiovascular risk despite maximal statin therapy raised the need to develop additional lipid-lowering drugs to be used in combination with or in alternative to statins in patients intolerant to the treatment. Several new drugs have been approved which have mechanisms of action different from statins or impact on different lipoprotein classes.
Keywords: Cardiovascular disease; Dyslipidemias; Ezetimibe; Familial hypercholesterolemia; Hypercholesterolemia; Hypertriglyceridemia; Lipid-lowering drugs; Low-density lipoprotein cholesterol; Low-density lipoprotein receptor; Proprotein convertase subtilisin/kexin type 9; Statins.
© 2020. The Author(s).